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The Dutch colorectal cancer (CRC) screening program started in 2014, inviting the target population biennially to perform a
fecal immunochemical test (FIT). We obtained prospectively collected data from the national screening information-system to
present the results of the second round (2016) and evaluate the impact of increasing the FIT cut-off halfway through the ﬁrst
round from 15 to 47 μg Hb/g feces on outcomes in the second round. Second round screening was done with a 47 μg Hb/g
feces FIT cut-off. Participants were classiﬁed based on ﬁrst round participation status as either FIT (15,47) or FIT (47,47)
participants, and previous nonparticipants. In total, 348,891 (75.9%) out of 459,740 invitees participated in the second round.
Participation rates were 93.4% among previous participants and 21.0% among previous non-participants. FIT(47,47)
participants had a signiﬁcantly higher detection rate of AN (15.3 vs. 10.4 per 1,000 participants) compared to FIT(15,47)
participants in the second round, while their cumulative detection rate of AN over two rounds was signiﬁcantly lower (45.6 vs.
52.6 per 1,000 participants). Our results showed that participation in the Dutch CRC screening program was consistently high
and that second round detection rates depended on the ﬁrst round FIT cut-off. The cumulative detection over two rounds was
higher among FIT(15,47) participants. These ﬁndings suggest that a substantial part of, but not all the missed ﬁndings in the
ﬁrst round due to the increased FIT cut-off were detected in the subsequent round.
Introduction
Many countries have recently introduced colorectal cancer (CRC)
screening with the aim to reduce CRC incidence and mortality.
These programs use different screening strategies.1 Colonoscopy
is the gold standard for detecting advanced neoplasia
(AN) because of its high sensitivity. However, colonoscopy is an
invasive procedure that demands extensive resources when used
for primary screening on a population level. Many countries
therefore prefer a non-invasive fecal test for primary screening,
followed by colonoscopy when tested positive. Of the currently
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available fecal tests, fecal immunochemical testing (FIT) is asso-
ciated with the highest participation and a high diagnostic
performance.2–6 Besides its superior characteristics compared to
other fecal testing screen modalities, FIT offers the advantage to
adjust the cut-off level to match local resources.7 It allows for
optimizing the balance between the number of true- and false-
positives, potentially inﬂuencing the detection rate.8,9 Modeling
studies based on real-life data reported that annual FIT at a low
cut-off is equally effective in reducing CRC-related mortality as
10-yearly primary colonoscopy screening.10 However, many
organized programs are currently forced to use a higher FIT
cut-off and a longer screening interval, often due to a limited
colonoscopy capacity.1,11,12
The Dutch FIT-based CRC screening program started in
2014 after extensive piloting in previous years. During the ﬁrst
months after the start, we observed a higher participation rate,
a higher FIT positivity rate and a lower positive predictive
value (PPV) compared to the results of the preceding pilot
studies. Since the referral rate exceeded the colonoscopy
capacity, the FIT cut-off was increased halfway during the ﬁrst
year, resulting in a lower positivity rate and a higher PPV for
AN.13 In this study we evaluated participation in the second
round and estimated the impact of the adjusted FIT cut-off in
the ﬁrst round, on screening outcomes in the second round.
This information is relevant for screening programs world-
wide when deciding on optimal implementation of FIT-
screening.
Materials and Methods
The design of the Dutch CRC screening program and its real-
time monitoring system have previously been described.13 In
summary, the target population consists of individuals aged
55–75 years old, who are invited every 2 years to perform a
FIT (FOB-Gold; Sentinel). The target population was invited
gradually by birth-cohort, with a projected rollout period of
5 years. Participants with a positive FIT (μg hemoglobin per
gram of feces above the cut-off) are referred for a pre-
colonoscopy intake. During this intake at the outpatient clinic,
individuals are informed about the colonoscopy procedure
and bowel preparation and assessed for eligibility. When con-
sidered eligible, individuals are scheduled for colonoscopy. In
case of the detection of adenoma or CRC, the participant was
referred for further treatment and colonoscopy surveillance.
Study population
In 2014, at the start of the screening program, birth cohorts
1951, 1949, 1947, 1939 and 1938, that respectively reached the
age of 63, 65, 67, 75 and 76 years, were invited for ﬁrst-round
screening. These birth cohorts were selected according to a
rollout strategy. We started in 2014 with the invitation of the
oldest age groups because it was their only opportunity to par-
ticipate. Persons aged 76 years were also included due to a
delayed implementation of the program. For the second
round, the same target group was re-invited in 2016, except
for the invitees who tested positive in the ﬁrst round, who had
become older than 75 years, or who had deregistered perma-
nently from the screening program. In the ﬁrst half year of
2014, a FIT cut-off of 15 μg hemoglobin per gram (Hb/g)
feces was used. This was increased to 47 μg in the second half
of 2014. In the second round, all FIT samples were analyzed
with a 47 μg FIT cut-off.
Data collection
Of all invitees of the ﬁrst round, data on participation status,
FIT-result (μg Hb/g feces), pre-colonoscopy intake and colo-
noscopy results in the ﬁrst and/or second screening round
were collected from the national screening information-system
(ScreenIT).
Outcomes
Participation rate, FIT positivity rate, PPV for AN and detec-
tion rate of AN in the second round were the primary out-
comes of this study. An invitee was considered a participant
when a FIT stool-sample was returned and a non-participant
when there was no response or when the invitee deregistered.
The participation rate was deﬁned as the number of partici-
pants divided by the number of individuals invited. The posi-
tivity rate was deﬁned as the number of participants with a
FIT-result at or above the cut-off divided by the number of
participants with an assessable FIT. The participation rate for
pre-colonoscopy intake was deﬁned as the number of persons
who attended the intake divided by the number of FIT-posi-
tives. The participation rate for colonoscopy was deﬁned as
the number of persons that underwent colonoscopy divided
by the number of persons with a positive FIT. AN was consid-
ered a relevant ﬁnding within the CRC screening program
and was deﬁned as CRC or advanced adenoma (AA).14 AA
was deﬁned as any adenoma with histology showing 25% or
greater villous component or high-grade dysplasia or an
What’s new?
In 2014, the Netherlands implemented colorectal cancer (CRC) screening based on non-invasive fecal immunochemical testing
(FIT), which offers a practical approach for population-based CRC detection. In the Dutch program’s ﬁrst round, to match local
resources, FIT cut-off was increased, resulting in reduced positivity rates and reduced colonoscopy referrals, at the cost of
missing advanced neoplasias. The current study shows that many of these missed advanced neoplasias were detected in
subsequent screening, suggesting that increased FIT cut-off had marginal impact on screening outcome. The ﬁndings could
beneﬁt other CRC screening programs in establishing effective FIT cut-offs.
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adenoma with size of 10 mm or larger. The PPV for AN was
calculated as the number of persons detected with AN divided
by the number of persons who underwent a colonoscopy. The
detection rate of AN was deﬁned as the number of persons
detected with AN of those who returned an assessable FIT.
Secondary outcomes were cumulative positivity rate, cumu-
lative detection rate of AN, number needed to scope
(NNScope) to detect AN in one patient, and the association
between concentration μg Hb/g feces (FIT-level) in the ﬁrst
round and screening-outcomes in the second round. Cumula-
tive positivity rate was deﬁned as the number of positive FIT
results over both rounds divided by the number of partici-
pants that returned an assessable FIT in both rounds or tested
positive in the ﬁrst round. The cumulative detection rate was
deﬁned as the number of CRC or AN detected over both
rounds in participants that returned an assessable FIT in both
rounds or tested positive in the ﬁrst round. The NNScope was
deﬁned as the number of performed colonoscopies divided by
the number of detected CRC or AN, over both rounds. The
FIT-level in the ﬁrst round was tested on the association with
positive FIT-result, PPV and detection of AN in the second
round.
Analyses
All invitees to the second round were analyzed for participa-
tion rate, positivity rate, participation rate of pre-colonoscopy
intake and colonoscopy, PPV for AN and detection rate of
AN. Primary outcomes were presented for three different sub-
groups: individuals that were tested with a FIT cut-off of
15 μg Hb/g feces in the ﬁrst round (FIT(15,47)), individuals
that were tested with a FIT cut-off of 47 μg Hb/g feces in the
ﬁrst round (FIT(47,47)) and individuals that did not partici-
pate in the ﬁrst round (FIT(np,47)). Secondary outcomes
excluded participants of the ﬁrst round of the oldest birth
cohorts (1938 and 1939), since those participants were not
part of the target population of 2016 and therefore not re-
invited. The cumulative positivity rate, cumulative detection
rate and NNScope over two screen-rounds were compared
between FIT(15,47) and FIT(47,47) participants of both
rounds. To assess the association between FIT-level in the ﬁrst
round and screening outcomes in the second round, the FIT-
results of ﬁrst round participants were categorized in 0, 1–14
and 15–46 μg Hb/g feces (the latter group was only applicable
to FIT(47,47) participants).
Descriptive statistics were computed of the primary out-
comes, including 95% conﬁdence intervals (95% CI). Differ-
ences between groups were tested for statistical signiﬁcance
(α < 0.05) using the Chi-square test or the Student’s t-test.
Age-adjusted rates for the primary outcomes and secondary
outcomes were calculated for groups with more than 50 invi-
tees, therefore only age groups of 65, 67 and 69 years old were
included. Because of substantially different age-distributions
between subgroups, the chi-square was not applicable. Instead,
differences between the age-adjusted rates were tested with
the standardized rate ratio (SRR).15,16 If the 95% CI of the
SRR includes 1, no signiﬁcant difference was observed
between the age-adjusted rates.
Multivariable logistic regression was performed to estimate
the odds ratios (ORs) of the FIT-level in the ﬁrst round on
screening outcomes in the second round, adjusted for gender
and age.
As sensitivity analyses, we (i) tested the outcomes on sig-
niﬁcant differences between gender and (ii) only included FIT
(47,47) participants to rule out selection bias (Supporting
Information Table S1 and S2). This bias could have occurred
because FIT(15,47) participants were invited in the ﬁrst half,
and FIT(47,47) participants in the second half of 2014.
Data analyses were performed using R version 3.4.1.
Ethical approval
The Dutch population screening program was approved by
the Ministry of Health and the Dutch population screening
act. According to the Central Committee on Research involv-
ing Human Subjects (CCMO), this study did not require
approval from an ethics committee in the Netherlands.
Returning the FIT is considered informed consent, in accor-
dance with the Dutch population screening act. No identifying
individual data were made available in this study.
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Results
In total, 459,740 individuals were invited for second-round
screening. Of those, 348,891 (75.9%) returned the FIT and
15,593 (4.5%) tested positive (Fig. 1 and Table 1). Out of the
FIT-positive participants, 14,102 (90.4%, 95% CI: 90.0–90.9%)
individuals attended the pre-colonoscopy intake, of which
13,163 (93.3%, 95% CI: 92.9–93.7%) were advised to undergo
colonoscopy. Eventually, 12,864 (82.5%, 95% CI: 81.9–83.1%)
participants of all individuals that tested FIT-positive under-
went colonoscopy, leading to detection of 832 CRCs and
4,576 AAs, resulting in a detection rate of 15.5 (95% CI:
15.1–15.9%) AN per 1,000 participants.
Participation
Of all 348,071 second-round invitees who participated in the
ﬁrst round, 325,392 (93.5%) also participated in the second
round (Table 2). Of all 111,669 second-round invitees who
did not participate in the ﬁrst round, a total of 23,499 (21.0%)
participated in the second round.
Yield of screening
Among second-round invitees that had also participated in
the ﬁrst round, there were 39,257 FIT(15,47) and 286,135 FIT
(47,47) participants (Table 2). FIT(15,47) participants in the
second round had a positivity rate of 3.3%, a PPV for AN of
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36.9% (95% CI: 34.1–39.8%), and a detection rate of AN of
10.4 (95% CI: 9.4–11.4%) per 1,000 participants. FIT(47,47)
participants had in the second round a higher positivity rate
of 4.3%, a higher PPV for AN of 41.2% (95% CI: 40.2–42.1%),
and a higher detection rate of AN of 15.0 (95% CI:
14.6–15.5%) per 1,000 participants. The SRR presented a sig-
niﬁcantly higher age-adjusted positivity rate (SRR: 1.3, 95%
CI: 1.1–1.5%) and age-adjusted detection rate of AN (SRR:
1.5, 95% CI: 1.2–1.9%) in FIT(47,47) participants of the sec-
ond round (Table 2). Differences in age-adjusted PPV
between the used cut-offs were non-signiﬁcant.
The FIT(np,47) participants of the second round showed a
high positivity rate of 7.9%, PPV of 54.9% (95% CI:
52.2–57.6%) for AN and detection rate of AN of 30.1 (95%
CI: 27.9–32.3%) per 1,000 participants (Table 2). All outcomes
were signiﬁcantly higher compared to second-round partici-
pants that had participated in the ﬁrst round.
Cumulative rates and NNScope
Of FIT(15,47) participants, 13.1% (95% CI: 12.8–13.4%) tested
positive in the ﬁrst (10.1%) or second (3.0%) round (cumula-
tive positivity rate). This cumulative positivity rate was higher
compared to the FIT(47,47) participants, of which 10.4%
(95% CI: 10.3–10.5%) tested positive in the ﬁrst (6.3%) or sec-
ond (4.1%) round. The age-adjusted cumulative positivity rate
over two rounds was signiﬁcantly higher in FIT(15,47) partici-
pants (SRR: 1.2 [1.2–1.3]).
Per 1,000 FIT(15,47) participants, CRC was detected in 7.5
(95% CI: 6.7–8.3%) participants in the ﬁrst (6.0) or second
(1.4) round and AN were detected in 52.6 (95% CI:
Figure 1. Flow chart of the second round of the Dutch colorectal cancer screening program.
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50.6–54.8%) participants in the ﬁrst (43.3) or second (9.3)
round (cumulative detection rate; Fig. 2). A lower cumulative
detection rate of CRC and AN was observed per 1,000 FIT
(47,47) participants, in which 6.9 (95% CI: 6.6–7.2%) partici-
pants were detected with CRC in the ﬁrst (4.8) or second (2.1)
round and 45.6 (95% CI: 44.8–46.3%) with AN in the ﬁrst
(31.5) or second (14.1) round. Age-adjusted rates showed a
non-signiﬁcant difference in the cumulative detection rate
over two rounds for CRC (SRR: 1.1, 95% CI: 0.8–1.4%), yet
signiﬁcantly more FIT(15,47) participants were detected with
AN (SRR: 1.2, 95% CI: 1.1–1.3%).
Over two rounds, 14.9 (95% CI: 14.5–15.3%) FIT(15,47)
participants and 12.7 (95% CI: 12.6–12.9%) FIT(47,47) partici-
pants needed to undergo colonoscopy (NNScope) to detect
CRC in one participant, with a signiﬁcant difference after age-
adjustment (SRR: 1.2, 95% CI: 1.1–1.3%). A similar pattern was
observed for the NNScope to detect AN in one partici-
pant (Fig. 3).
Yield by previous FIT result
The positivity rate, PPV and detection rate in the second round
was strongly related to the concentration of Hb detected in
feces in the ﬁrst round. Participants with a FIT-level in the ﬁrst
round between 15 and 47 μg Hb/g feces showed a positivity
rate of 23.3%, a PPV for AN of 60.3% and a detection rate of
AN of 120.3 per 1,000 participants in the second round
(Table 3). The second round outcomes in these participants
were signiﬁcantly higher than in participants with a FIT-level
below 15 μg in the ﬁrst round. Compared to participants with
no (0 μg) detectable Hb in their feces sample in the ﬁrst round,
a participant with a FIT-level between 15 and 47 μg was
remarkably more likely to test FIT-positive (OR 11.9, 95% CI:
11.3–12.5%) or have an AN detected during colonoscopy
(OR 23.2, 95% CI: 21.5–25.1%). While the sensitivity analyses
ruled out selection bias, it pointed out signiﬁcant differences
between male and female participants (Supporting Information
Tables S1 and S2). However, this did not change the conclu-
sion, as both genders presented a strong correlation between
ﬁrst round FIT-result and outcomes in the subsequent round.
Discussion
This study presents the results of the second round of the
Dutch FIT-based CRC screening program and evaluates the
impact of increasing the FIT cut-off in the ﬁrst round on the
yield of the second round.
We observed a consistently high participation as almost all
ﬁrst-round participants also participated in the second round.
The detection rate of AN in the second round was signiﬁ-
cantly higher in FIT(47,47) participants compared to FIT
(15,47) participants. Nevertheless, the cumulative detection
rate of AN over two rounds was signiﬁcantly lower in FIT
(47,47) participants. We found a strong correlation between
the concentration μg Hb/g feces in the ﬁrst round and the
detection of AN in the subsequent round.Ta
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The Dutch government was the ﬁrst to change the FIT cut-
off in a running national CRC screening program. Therefore
we are the only country yet in which evaluation of the program
can demonstrate the impact of adjusting the FIT cut-off on the
yield at a population level. The main reason to increase the FIT
cut-off during the ﬁrst round was to reduce colonoscopy
demand and the proportion of false-positive FIT-results. As
previously reported, this indeed successfully decreased the posi-
tivity rate and increased the PPV in ﬁrst round FIT(47,47) par-
ticipants, at the cost of a lower detection rate.13 We
demonstrated in the current study that, cumulatively, the detec-
tion rate over two rounds was still lower in FIT(47,47) partici-
pants. However, we also observed that the difference in
cumulative detection rate of AN between FIT(47,47) and FIT
(15,47) participants decreased from 11.8 AN per 1,000 partici-
pants in the ﬁrst round, to 7.0 AN per 1,000 participants in the
second round. This means that a substantial part of the missed
lesions in the ﬁrst screening-round due to the increased FIT
cut-off from 15 to 47 μg Hb/g feces are detected at the subse-
quent round. The cumulative detection rate of CRC over two
rounds in FIT(47,47) and FIT(15,47) participants was almost
similar. If the difference in cumulative detection rate of AN
between FIT(47,47) and FIT(15,47) participants keeps declining
per subsequent screening, the impact of adjusting the FIT cut-
off on the cumulative detection rate might become insigniﬁcant
within one or two subsequent screening rounds. However, it is
unclear if the higher cut-off resulted in more interval cancers
and if the detected CRCs in the second round were still diag-
nosed in an early stage, which is a prerequisite for screening to
be effective. Therefore, interval cancers and data on stage distri-
bution have to be evaluated, before making ﬁnal conclusions in
this respect. Unfortunately, these data are not available yet.
The effect of increasing the cut-off in the older birth cohorts,
75 and 76 years of age, which were not re-invited for a second
round as they exceeded the target age, should be assessedTa
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Figure 2. Cumulative detection rate of colorectal cancer and
advanced neoplasia over two rounds of screening.
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separately. As the missed lesions in FIT(47,47) participants of
these birth cohorts will not be detected in a subsequent round,
they might potentially progress to symptomatic CRC.
The reported participation rate (75.9%) in the Netherlands
can be considered the highest in a subsequent round, even
higher than seen in the Dutch CRC screening pilots.17–19 How-
ever, this outcome is overestimated by approximately 2%, since
the calculation of participation rate excluded invitees who
deregistered permanently during the ﬁrst round and were
therefore not invited to the second round. The favorable partic-
ipation rate has been attributed to the non-invasive screening
modality and organizational structure of the program. The con-
sistent high participation rate and the resulting detection rates
of AA make it likely that the modeled long-term effects in
reducing CRC related mortality will be achieved.10 The consis-
tent participation also allowed for missed ﬁndings in the ﬁrst
round due to the increased cut-off to be detected in the second
round. For FIT-based CRC screening programs with a lower
repeated participation rate, increasing the FIT cut-off might
have a larger impact.
The strong correlation between the level of Hb concentra-
tion of a negative FIT result and the chance of detecting AN
in the subsequent round suggests an excellent opportunity for
more personalized FIT screening based on Hb concentration.
For example, the screening interval or FIT cut-off of partici-
pants with no detectable blood (0 μg Hb/g feces) could poten-
tially be increased. On the other hand, participants with a FIT
result just below the cut-off level might proﬁt from more
intense screening by shortening the screening interval. In con-
cordance with our data, a similar association between FIT
level and outcomes in the subsequent rounds has previously
been presented by a Dutch, Spanish and Taiwanese study.20–22
Important strengths of our study are the nation-wide imple-
mentation of the screening program, the large sample size and
the well-developed registration, therefore providing accurate
data. Nevertheless, three limitations are noteworthy. As men-
tioned before, data on stage distribution are lacking, which
would provide important information on the potential conse-
quences of missed lesions in the ﬁrst round caused by the
increased FIT cut-off. These data will be available in the near
future. Second, for a ﬁnal verdict on the consistency of the par-
ticipation and the cumulative outcomes, information on more
consecutive rounds is needed. Finally, not every birth cohort
has been invited yet for the Dutch CRC screening program,
hence conclusions are mainly based on a few age groups.
Notwithstanding these limitations, we are the ﬁrst to pre-
sent on how using a different FIT cut-off in the ﬁrst round
impacts the outcomes of a subsequent round. Our ﬁndings are
of value to other FIT-based CRC screening programs consid-
ering an appropriate cut-off in their setting, in particular
when the used FIT cut-off is within the same range.
In conclusion, participation in the Dutch CRC screening pro-
gram was high and consistent. Our results show that using a
higher FIT cut-off in CRC screening has limited impact on the
yield of screening because a substantial part of AN will be
detected in subsequent rounds. To conﬁrm whether these AN
Figure 3. Number of participants that underwent colonoscopy
(number needed to scope) over two rounds of screening to detect
one colorectal cancer or advanced neoplasia.
Table 3. Yield of the second round relative to FIT results of the first round
First screening round FIT
result (Hb/g feces) 0 μg >0 and <15 μg ≥15 and <47 μg p-value
Total 248,310 66,030 10,961
Positivity rate
n (%) 6,000 (2.4) 5,187 (7.9) 2,553 (23.3) <0.001
Odds-ratio (95% CI) – 3.4 (3.3–3.5)1 11.9 (11.3–12.5)1
PPV AN
n (%) 1,390 (27.9) 1,993 (45.7) 1,319 (60.3) <0.001
Odds-ratio (95% CI) – 2.2 (2.0–2.4) 3.9 (3.5–4.3)
Detection rate AN
n (per 1,000 participants) 1,390 (5.6) 1,993 (30.2) 1,319 (120.3) <0.001
Odds-ratio (95% CI) – 5.4 (5.0–5.8)1 23.2 (21.5–25.1)1
Note: Odds-ratio are adjusted for age and gender.
1Significant interaction between male and female gender (see Supporting Information).
Abbreviations: AN, advanced neoplasm; FIT, fecal immunochemical test; PPV, positive predictive value.
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are still detected in an early stage, retrieving more information
on the stage distribution of CRCs detected in the second round
is important.
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